Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome
Key facts
- Who runs it
- Duke University
- Where
- Durham, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 2,800 people, planned
- Started
- Jun 2006
- Expected to end
- Mar 2029
- Type of study
- Observational, 3 groups
- Record updated
- 29 May 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Persistent presence of an antiphospholipid antibody, as defined by one or both of the following criteria:; Medium or high anticardiolipin antibody level in the blood on two or more occasions at least 6 weeks apart; Presence of lupus anticoagulant in the plasma on two or more occasions at least 6 weeks apart
- Presence of clinical symptoms seen in patients with APS, including vascular thrombosis (one or more clinical episodes of arterial, venous, or small vessel thrombosis in any tissue or organ) and/or pregnancy morbidity, defined as any of the following:; One or more unexplained deaths of a morphologically normal fetus at or beyond the 10th week of gestation, with normal fetus morphology documented by ultrasound or direct examination or the fetus; One or more premature births of a morphologically normal baby at or before the 34th week of gestation because of severe pre-eclampsia, eclampsia, or severe placental insufficiency; Three or more unexplained consecutive spontaneous abortions before the 10th week of gestation, with maternal anatomic or hormonal abnormalities and paternal and maternal chromosomal causes excluded
- People who have elevated antiphospholipid antibody levels but do not fully meet clinical criteria for APS, and do have affected family members, will be considered for enrollment
Who cannot take part
- No documented presence of antiphospholipid antibody
Where in United States
- Duke University Medical CenterDurham, United StatesContact: Thomas L. Ortel, MD, PhD (principal investigator)Taking people
About the trial
What the trial wants to find out
Antiphospholipid antibody syndrome (APS) is characterized by the presence of antiphospholipid antibodies, which are proteins in the blood that interfere with the body's ability to perform normal blood clotting. Clinical problems associated with antiphospholipid antibodies include an increased risk for the formation of blood clots in the lungs or deep veins of the legs, stroke, heart attack, and recurrent miscarriages. It is possible that some people with APS have a genetic predisposition for developing the syndrome. This study will use a genetic strategy to identify potential inherited risk factors for the development of APS by recruiting people with APS who have family members also affected by the syndrome or by another autoimmune disorder, such as lupus or rheumatoid arthritis.
The 3 groups in the trial
- 1
Individuals with APS who also have one or more of their family members affected specifically by APS
- 2
Individuals with APS who also have one or more of their family members affected by another type of autoimmune disorder, such as lupus or rheumatoid arthritis.
- 3
Individuals with APS and no family or no family affected with APS or another autoimmune disorder
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Genetics of Antiphospholipid Antibody Syndrome
- Record updated
- 29 May 2026